Login Register Cart 0
Generic placeholder image

CNS & Neurological Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5273
ISSN (Online): 1996-3181

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Meta-Analysis

Safety and Efficacy of Calcitonin Gene-related Peptide Receptor Antagonists and Selective Serotonin Receptor Agonist in the Management of Migraine: A Systematic Review and Meta-analysis

Author(s): Pooja Singh, Rakesh Kumar Ponnada, Ruchika Sharma, Bommaraju Sumadhura, Anoop Kumar* and Ashok Kumar Datusalia*

Volume 23, Issue 12, 2024

Published on: 05 June, 2024

Page: [1474 - 1487] Pages: 14

DOI: 10.2174/0118715273304677240529062909

Price: $65

Abstract

Background: Recently, US Food and Drug Administration (FDA) has approved calcitonin gene-related peptide receptor antagonists (rimegepant, and ubrogepant), and selective serotonin receptor agonists (lasmiditan) in the management of migraine. However, the exact safety and efficacy profile of these drugs is unclear so far.

Methods: The study’s primary objective was to determine the exact safety and efficacy profile. The overall estimate was calculated in terms of risk ratios using a suitable model. The subgroup analysis was also performed to check the effect of individual drugs on the outcome, whereas sensitivity analysis was performed to check the effects of outliers on the outcome. All the analyses were performed using Rev Man 5. The drugs have shown significant improvement in efficacy parameters (pain freedom, most bothersome symptoms, phonophobia, nausea, and photophobia).

Results: The subgroup analysis results have shown significant improvement in all efficacy parameters in the rimegepant and ubrogepant groups. The effect of ubrogepant on safety parameters was found to be non-significant, indicating a better safety profile of ubrogepant than lasmiditan.

Conclusion: The sensitivity analysis results have shown no effect of outliers on the efficacy parameters. Based on the available evidence, recently approved drugs are effective in the treatment of migraine, however, associated with few adverse drug reactions.

« Previous Next »
[1]
Peters GL. Migraine overview and summary of current and emerging treatment options. Am J Manag Care 2019; 25(2) (Suppl.): S23-34.
[PMID: 30681821]
[2]
Stewart WF, Lipton RB, Liberman J. Variation in migraine prevalence by race. Neurology 1996; 47(1): 52-9.
[http://dx.doi.org/10.1212/WNL.47.1.52] [PMID: 8710124]
[3]
Lipton RB, Bigal ME. The epidemiology of migraine. Am J Med 2005; 118 (Suppl. 1): 3S-10S.
[PMID: 15841882]
[4]
Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: Data from the American Migraine Study II. Headache 2001; 41(7): 646-57.
[http://dx.doi.org/10.1046/j.1526-4610.2001.041007646.x] [PMID: 11554952]
[5]
Ashina M, Katsarava Z, Do TP, et al. Migraine: Epidemiology and systems of care. Lancet 2021; 397(10283): 1485-95.
[http://dx.doi.org/10.1016/S0140-6736(20)32160-7] [PMID: 33773613]
[6]
Agostoni EC, Barbanti P, Calabresi P, et al. Current and emerging evidence-based treatment options in chronic migraine: A narrative review. J Headache Pain 2019; 20(1): 92.
[http://dx.doi.org/10.1186/s10194-019-1038-4] [PMID: 31470791]
[7]
Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: A randomised, phase 3, double-blind, placebo-controlled trial. Lancet 2019; 394(10200): 737-45.
[http://dx.doi.org/10.1016/S0140-6736(19)31606-X] [PMID: 31311674]
[8]
Goadsby PJ, Blumenfeld AM, Lipton RB, et al. Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications. Cephalalgia 2021; 41(5): 546-60.
[http://dx.doi.org/10.1177/0333102420970523] [PMID: 33241721]
[9]
Kuca B, Silberstein SD, Wietecha L, et al. Lasmiditan is an effective acute treatment for migraine. Neurology 2018; 91(24): e2222-32.
[http://dx.doi.org/10.1212/WNL.0000000000006641] [PMID: 30446595]
[10]
Prakash S, Rana K. Lasmiditan: A new promising drug in migraine. Ann Indian Acad Neurol 2021; 24(2): 126-7.
[http://dx.doi.org/10.4103/aian.AIAN_30_21] [PMID: 34220050]
[11]
Haidich AB. Meta-analysis in medical research. Hippokratia 2010; 14 (Suppl. 1): 29-37.
[PMID: 21487488]
[12]
National Heart Lung and Blood Institute (NIH). Study quality assessment tools. 2023. Available From: https://www.nhlbi.nih.gov/
[13]
Johnston KM, Powell L, Popoff E, et al. Rimegepant, ubrogepant, and lasmiditan in the acute treatment of migraine examining the benefit-risk profile using number needed to treat/harm. Clin J Pain 2022; 38(11): 680-5.
[http://dx.doi.org/10.1097/AJP.0000000000001072] [PMID: 36125279]
[14]
Jakate A, Boinpally R, Butler M, Lu K, McGeeney D, Periclou A. Evaluation of the pharmacokinetic interaction of ubrogepant coadministered with sumatriptan and of the safety of ubrogepant with triptans. Headache 2020; 60(7): 1340-50.
[http://dx.doi.org/10.1111/head.13862] [PMID: 32573795]
[15]
Clemow DB, Hochstetler HM, Dong Y, Hauck P, Peres MFP, Ailani J. Effect of a change in lasmiditan dose on efficacy and safety in patients with migraine. Postgrad Med 2021; 133(4): 449-59.
[http://dx.doi.org/10.1080/00325481.2020.1860619] [PMID: 33730977]
[16]
Dodick DW, Lipton RB, Ailani J, et al. Ubrogepant, an acute treatment for migraine, improved patient-reported functional disability and satisfaction in 2 single-attack phase 3 randomized trials, achieve I and II. Headache 2020; 60(4): 686-700.
[http://dx.doi.org/10.1111/head.13766] [PMID: 32073660]
[17]
Dodick DW, Lipton RB, Ailani J, et al. Ubrogepant for the treatment of migraine. N Engl J Med 2019; 381(23): 2230-41.
[http://dx.doi.org/10.1056/NEJMoa1813049] [PMID: 31800988]
[18]
Krege JH, Rizzoli PB, Liffick E, et al. Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN. Cephalalgia 2019; 39(8): 957-66.
[http://dx.doi.org/10.1177/0333102419855080] [PMID: 31166697]
[19]
Knievel K, Buchanan AS, Lombard L, et al. Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans. Cephalalgia 2020; 40(1): 19-27.
[http://dx.doi.org/10.1177/0333102419889350] [PMID: 31744319]
[20]
Loo LS, Plato BM, Turner IM, et al. Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: Findings from the phase 3 trials (SAMURAI and SPARTAN). BMC Neurol 2019; 19(1): 191.
[http://dx.doi.org/10.1186/s12883-019-1420-5] [PMID: 31409292]
[21]
Färkkilä M, Diener HC, Géraud G, et al. Efficacy and tolerability of lasmiditan, an oral 5-HT1F receptor agonist, for the acute treatment of migraine: A phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol 2012; 11(5): 405-13.
[http://dx.doi.org/10.1016/S1474-4422(12)70047-9] [PMID: 22459549]
[22]
Ashina M, Vasudeva R, Jin L, et al. Onset of efficacy following oral treatment with lasmiditan for the acute treatment of migraine: Integrated results from 2 randomized double-blind placebo-controlled phase 3 clinical studies. Headache 2019; 59(10): 1788-801.
[http://dx.doi.org/10.1111/head.13636] [PMID: 31529622]
[23]
Lipton RB, Croop R, Stock EG, et al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med 2019; 381(2): 142-9.
[http://dx.doi.org/10.1056/NEJMoa1811090] [PMID: 31291516]
[24]
Lipton RB, Dodick DW, Ailani J, et al. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: The ACHIEVE II randomized clinical trial. JAMA 2019; 322(19): 1887-98.
[http://dx.doi.org/10.1001/jama.2019.16711] [PMID: 31742631]
[25]
Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: A phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet 2021; 397(10268): 51-60.
[http://dx.doi.org/10.1016/S0140-6736(20)32544-7] [PMID: 33338437]
[26]
Shapiro RE, Hochstetler HM, Dennehy EB, et al. Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: Post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials. J Headache Pain 2019; 20(1): 90.
[http://dx.doi.org/10.1186/s10194-019-1044-6] [PMID: 31464581]
[27]
Marcus R, Goadsby PJ, Dodick D, Stock D, Manos G, Fischer TZ. BMS-927711 for the acute treatment of migraine: A double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia 2014; 34(2): 114-25.
[http://dx.doi.org/10.1177/0333102413500727] [PMID: 23965396]
[28]
Voss T, Lipton RB, Dodick DW, et al. A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia 2016; 36(9): 887-98.
[http://dx.doi.org/10.1177/0333102416653233] [PMID: 27269043]
[29]
Tepper SJ, Vasudeva R, Krege JH, et al. Evaluation of 2-hour post-dose efficacy of lasmiditan for the acute treatment of difficult-to-treat migraine attacks. Headache 2020; 60(8): 1601-15.
[http://dx.doi.org/10.1111/head.13897] [PMID: 32634275]
[30]
Tepper SJ, Krege JH, Lombard L, et al. Characterization of dizziness after lasmiditan usage: Findings from the SAMURAI and SPARTAN acute migraine treatment randomized trials. Headache 2019; 59(7): 1052-62.
[http://dx.doi.org/10.1111/head.13544] [PMID: 31152441]
[31]
Sakai F, Takeshima T, Homma G, Tanji Y, Katagiri H, Komori M. Phase 2 randomized placebo‐controlled study of lasmiditan for the acute treatment of migraine in Japanese patients. Headache 2021; 61(5): 755-65.
[http://dx.doi.org/10.1111/head.14122] [PMID: 33990951]
[32]
Wilbraham D, Berg PH, Tsai M, et al. Abuse potential of lasmiditan: A phase 1 randomized, placebo- and alprazolam-controlled crossover study. J Clin Pharmacol 2020; 60(4): 495-504.
[http://dx.doi.org/10.1002/jcph.1543] [PMID: 31745991]
[33]
Ashina M, Reuter U, Smith T, et al. Randomized, controlled trial of lasmiditan over four migraine attacks: Findings from the CENTURION study. Cephalalgia 2021; 41(3): 294-304.
[http://dx.doi.org/10.1177/0333102421989232] [PMID: 33541117]
[34]
Hutchinson S, Silberstein SD, Blumenfeld AM, et al. Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and II. Cephalalgia 2021; 41(9): 979-90.
[http://dx.doi.org/10.1177/03331024211000311] [PMID: 33874756]
[35]
Blumenfeld AM, Goadsby PJ, Dodick DW, et al. Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis. Headache 2021; 61(3): 422-9.
[http://dx.doi.org/10.1111/head.14089] [PMID: 33749826]
[36]
Reuter U, Krege JH, Lombard L, et al. Lasmiditan efficacy in the acute treatment of migraine was independent of prior response to triptans: Findings from the CENTURION study. Cephalalgia 2022; 42(1): 20-30.
[http://dx.doi.org/10.1177/03331024211048507] [PMID: 34644189]
[37]
Goadsby PJ, Tepper SJ, Watkins PB, et al. Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: Randomized, placebo-controlled trial in healthy adults. Cephalalgia 2019; 39(14): 1753-61.
[http://dx.doi.org/10.1177/0333102419869918] [PMID: 31537107]
[38]
Goadsby PJ, Wietecha LA, Dennehy EB, et al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain 2019; 142(7): 1894-904.
[http://dx.doi.org/10.1093/brain/awz134] [PMID: 31132795]
[39]
Loo LS, Ailani J, Schim J, et al. Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: Findings from SAMURAI and SPARTAN, two randomized phase 3 trials. J Headache Pain 2019; 20(1): 84.
[http://dx.doi.org/10.1186/s10194-019-1032-x] [PMID: 31340760]
[40]
Doty EG, Krege JH, Jin L, Raskin J, Halker Singh RB, Kalidas K. Sustained responses to lasmiditan: Results from post-hoc analyses of two Phase 3 randomized clinical trials for acute treatment of migraine. Cephalalgia 2019; 39(12): 1569-76.
[http://dx.doi.org/10.1177/0333102419859313] [PMID: 31266353]
[41]
Lipton RB, Lombard L, Ruff DD, et al. Trajectory of migraine-related disability following long-term treatment with lasmiditan: Results of the GLADIATOR study. J Headache Pain 2020; 21(1): 20.
[http://dx.doi.org/10.1186/s10194-020-01088-4] [PMID: 32093628]
[42]
Ha DK, Kim MJ, Han N, Kwak JH, Baek I. Comparative efficacy of oral calcitonin-gene-related peptide antagonists for the treatment of acute migraine: Updated meta-analysis. Clin Drug Investig 2021; 41(2): 119-32.
[http://dx.doi.org/10.1007/s40261-020-00997-1] [PMID: 33426614]
[43]
Raposio E, Raposio G, Del Duchetto D, Tagliatti E, Cortese K. Morphologic vascular anomalies detected during migraine surgery. J Plast Reconstr Aesthet Surg 2022; 75(11): 4069-73.
[http://dx.doi.org/10.1016/j.bjps.2022.08.036] [PMID: 36167709]
[44]
Huang T, Xu Y, Chen Y, et al. Efficacy and safety of calcitonin gene‐related peptide antagonists in migraine treatment: A meta‐analysis. Brain Behav 2022; 12(4): e2542.
[http://dx.doi.org/10.1002/brb3.2542] [PMID: 35261165]
[45]
D V, Sharma A, Kumar A, Flora SJS. Neurological manifestations in COVID-19 patients: A meta-analysis. ACS Chem Neurosci 2021; 12(15): 2776-97.
[http://dx.doi.org/10.1021/acschemneuro.1c00353] [PMID: 34260855]
[46]
Messina R, Goadsby PJ. CGRP – a target for acute therapy in migraine: Clinical data. Cephalalgia 2019; 39(3): 420-7.
[http://dx.doi.org/10.1177/0333102418768095] [PMID: 29616830]
[47]
Holland PR, Goadsby PJ. Targeted CGRP Small molecule antagonists for acute migraine therapy. Neurotherapeutics 2018; 15(2): 304-12.
[http://dx.doi.org/10.1007/s13311-018-0617-4] [PMID: 29556965]
[48]
Do TP, Guo S, Ashina M. Therapeutic novelties in migraine: New drugs, new hope? J Headache Pain 2019; 20(1): 37.
[http://dx.doi.org/10.1186/s10194-019-0974-3] [PMID: 30995909]
[49]
Hou M, Xing H, Li C, et al. Short-term efficacy and safety of lasmiditan, a novel 5-HT1F receptor agonist, for the acute treatment of migraine: A systematic review and meta-analysis. J Headache Pain 2020; 21(1): 66.
[http://dx.doi.org/10.1186/s10194-020-01138-x] [PMID: 32503415]
[50]
Yang CP, Liang CS, Chang CM, et al. Comparison of new pharmacologic agents with triptans for treatment of migraine: A systematic review and meta-analysis. JAMA Netw Open 2021; 4(10): e2128544.
[http://dx.doi.org/10.1001/jamanetworkopen.2021.28544] [PMID: 34633423]
[51]
Srivastava R, Kumar A. Use of aspirin in reduction of mortality of COVID‐19 patients: A meta‐analysis. Int J Clin Pract 2021; 75(11): e14515.
[http://dx.doi.org/10.1111/ijcp.14515] [PMID: 34118111]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy